Anpario PLC (GB00B3NWT178)

Overview

Antisense Therapeutics Limited is an Australian-based biopharmaceutical company focused on the discovery, development, and commercialization of antisense pharmaceuticals. Since its inception in 2000, the company has dedicated itself to creating therapies that target genetic disorders and diseases by manipulating gene expression. Its operations are rooted in innovative research to provide treatments for conditions with significant unmet medical needs. The company's strategic approach combines advanced antisense technology with a strong scientific foundation, aiming to lead in the niche market of RNA-targeted drug discovery.

Products and Services

• ATL1102

  ATL1102 is an antisense inhibitor targeting CD49d, a molecule involved in inflammation. Currently in Phase IIa clinical trials, ATL1102 is designed for treating multiple sclerosis (MS). Due to its mechanism of action, it also holds potential for the treatment of Duchenne Muscular Dystrophy, asthma, and other conditions characterized by excessive inflammation. Through specifically targeting CD49d mRNA, ATL1102 aims to mitigate the inflammatory responses implicated in these diseases.

• ATL1103

  A second-generation antisense drug, ATL1103 is designed to inhibit the expression of the growth hormone receptor (GHR), effectively reducing the levels of insulin-like growth factor-I (IGF-I) in the bloodstream. This reduction is crucial for treating conditions associated with excessive growth hormone action, such as acromegaly. Having completed Phase II clinical trials, ATL1103 showcases the ability of antisense technologies to address endocrine disorders by fine-tuning hormone levels.